0000000000536424

AUTHOR

G. Piras

showing 3 related works from this author

Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes

2018

Background Albuminuria has been classically considered a marker of kidney damage progression in diabetic patients and it is routinely assessed to monitor kidney function. However, the role of a mild GFR reduction on the development of stage ≥3 CKD has been less explored in type 1 diabetes mellitus (T1DM) patients. Aim of the present study was to evaluate the prognostic role of kidney disease measures, namely albuminuria and reduced GFR, on the development of stage ≥3 CKD in a large cohort of patients affected by T1DM. Methods A total of 4284 patients affected by T1DM followed-up at 76 diabetes centers participating to the Italian Association of Clinical Diabetologists (Associazione Medici D…

AdultMaleNephrologymedicine.medical_specialtyendocrine system diseasesRenal function030209 endocrinology & metabolism030204 cardiovascular system & hematologylcsh:RC870-923Kidneyurologic and male genital diseasesGFR03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineDiabetes mellitusmedicineHumansAlbuminuriaDiabetic kidney diseaseKidneyType 1 diabetesurogenital systembusiness.industryIncidence (epidemiology)Middle Agedlcsh:Diseases of the genitourinary system. Urologymedicine.diseasefemale genital diseases and pregnancy complicationsAlbuminuria Diabetic kidney disease GFR NephrologyDiabetes Mellitus Type 1medicine.anatomical_structureItalyNephrologyDisease ProgressionAlbuminuriaFemalemedicine.symptombusinessResearch ArticleFollow-Up StudiesGlomerular Filtration RateKidney disease
researchProduct

Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double-blind, placebo-controlled trial

2022

Background and purpose: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options. RNS60 is an immunomodulatory and neuroprotective investigational product that has shown efficacy in animal models of ALS and other neurodegenerative diseases. Its administration has been safe and well tolerated in ALS subjects in previous early phase trials. Methods: This was a phase II, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial. Participants diagnosed with definite, probable or probable laboratory-supported ALS were assigned to receive RNS60 or placebo administered for 24 weeks intravenously (375 ml) once a week and via nebul…

treatmentAmyotrophic Lateral Sclerosisplacebo-controlledNeurodegenerative DiseasesALS; clinical trial; placebo-controlled; randomized; treatmentclinical trialTreatment OutcomeNeurologyDouble-Blind MethodrandomizedQuality of LifeHumansSettore MED/26 - NeurologiaNeurology (clinical)ALSBiomarkers
researchProduct

Co-circulation of SARS-CoV-2 Alpha and Gamma variants in Italy, February and March 2021

2022

Background Several SARS-CoV-2 variants of concern (VOC) have emerged through 2020 and 2021. There is need for tools to estimate the relative transmissibility of emerging variants of SARS-CoV-2 with respect to circulating strains. Aim We aimed to assess the prevalence of co-circulating VOC in Italy and estimate their relative transmissibility. Methods We conducted two genomic surveillance surveys on 18 February and 18 March 2021 across the whole Italian territory covering 3,243 clinical samples and developed a mathematical model that describes the dynamics of co-circulating strains. Results The Alpha variant was already dominant on 18 February in a majority of regions/autonomous provinces (…

EpidemiologySARS-CoV-2Public Health Environmental and Occupational HealthCOVID-19co-circulation; lineage; SARS-CoV-2 variant of concern; transmissibility; Humans; Italy; Models Theoretical; COVID-19; SARS-CoV-2Models TheoreticalSettore MED/42 - Igiene Generale E ApplicataSARS-CoV-2 variant of concern; co-circulation; lineage; transmissibility; Humans; Italy; Models Theoretical; COVID-19; SARS-CoV-2SARS-CoV-2 variant of concernSARS-COV-2 VARIANT OF CONCERN CO-CIRCULATION LINEAGE TRANSMISSIBILITY HUMANS ITALY MODELS THEORETICAL COVID-19 SARS-COV-2ItalyTheoreticalModelsVirologytransmissibilityHumansHumanco-circulationlineage
researchProduct